EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pressure BioSciences EBITDA Margin % Related Terms
Pressure BioSciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pressure BioSciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBIO vs EMED, CUTRQ, MHTX: EBITDA Margin % Comparison
For the Medical Devices subindustry, Pressure BioSciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pressure BioSciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pressure BioSciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pressure BioSciences (PBIO) has a EBITDA Margin % of -827.49% as of Jun. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pressure BioSciences and its competitors.
Is Pressure BioSciences' EBITDA Margin % too high?
Pressure BioSciences' current EBITDA Margin % is -827.49%. Overall, Pressure BioSciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Pressure BioSciences' EBITDA Margin % compare to EMED and CUTRQ?
Pressure BioSciences' EBITDA Margin % of -827.49% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pressure BioSciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pressure BioSciences's current EBITDA Margin % is -827.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pressure BioSciences stock overvalued right now?
Pressure BioSciences (PBIO) has a current EBITDA Margin % of -827.49%. The current EBITDA Margin % is -827.49%. Pressure BioSciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pressure BioSciences (PBIO), the current EBITDA Margin % is -827.49% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of enabling, pressure-based platform solutions for the world-wide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
12GF Score
Get the complete analysis for PBIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBIO has been successfully added to your 
